ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,445.80
0.21%
Dow Jones
39,850.51
0.74%
Gold vs US Dollar
2,386.40
1.32%
Brent Oil
82.665
0.14%
Bitcoin
65,810.31
6.93%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Navidea Biopharmaceuticals Inc (NAVB)

  7. Navidea Biopharmaceuticals Inc (NAVB) News

Navidea Biopharmaceuticals (NAVB)

Navidea Biopharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:NAVB
DateTimeSourceHeadlineSymbolCompany
21/12/202320:32Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]AMEX:NAVBNavidea Biopharmaceuticals Inc
05/12/202323:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
01/12/202316:49Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
16/11/202321:55Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
23/10/202318:56Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
06/10/202302:01Business WireNavidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common StockAMEX:NAVBNavidea Biopharmaceuticals Inc
05/10/202321:21Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NAVBNavidea Biopharmaceuticals Inc
15/09/202320:42Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsAMEX:NAVBNavidea Biopharmaceuticals Inc
11/09/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:NAVBNavidea Biopharmaceuticals Inc
15/08/202322:53Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
11/08/202321:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]AMEX:NAVBNavidea Biopharmaceuticals Inc
10/08/202314:29Business WireNavidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing PanelAMEX:NAVBNavidea Biopharmaceuticals Inc
08/08/202321:23Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
31/07/202314:32Business WireNavidea Biopharmaceuticals, Inc. Presses Ahead, Embraces OpportunitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
29/07/202301:23Business WireNavidea Biopharmaceuticals, Inc. Announces NYSE American Has Commenced Delisting Proceedings and Intent to Appeal NYSE American DeterminationAMEX:NAVBNavidea Biopharmaceuticals Inc
28/07/202322:10Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
27/07/202322:20Business WireNavidea Biopharmaceuticals, Inc. Hires Craig A. Dais, CPA as Chief Financial OfficerAMEX:NAVBNavidea Biopharmaceuticals Inc
17/07/202323:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
17/07/202323:00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
13/07/202322:27Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
13/07/202322:09Business WireNavidea Biopharmaceuticals, Inc. Welcomes Dana J Moss, JD to Board of Directors; Amit Bhalla Steps DownAMEX:NAVBNavidea Biopharmaceuticals Inc
06/07/202321:39Edgar (US Regulatory)Form 8-K - Current reportAMEX:NAVBNavidea Biopharmaceuticals Inc
03/07/202322:30Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsAMEX:NAVBNavidea Biopharmaceuticals Inc
03/07/202321:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:NAVBNavidea Biopharmaceuticals Inc
30/06/202321:01Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]AMEX:NAVBNavidea Biopharmaceuticals Inc
30/06/202315:46Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)AMEX:NAVBNavidea Biopharmaceuticals Inc
30/06/202315:46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesAMEX:NAVBNavidea Biopharmaceuticals Inc
30/06/202314:16Business WireNavidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain AssetsAMEX:NAVBNavidea Biopharmaceuticals Inc
16/06/202322:23Edgar (US Regulatory)Current Report Filing (8-k)AMEX:NAVBNavidea Biopharmaceuticals Inc
16/06/202322:00Edgar (US Regulatory)Securities Registration (section 12(g)) (8-a12g)AMEX:NAVBNavidea Biopharmaceuticals Inc
 Showing the most relevant articles for your search:AMEX:NAVB

Your Recent History

BIT
W237S8
UBS
USOTC
STRY
Starry (PK)
NASDAQ
BIOV
BIOVENTUS INC.
NYSE
XVF
Lehman Abs 8.00 Ford
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved